Reproductive Panel (10 targets)
Reproductive Panel (10 targets)

[Product Name]

10 Reproductive Tract Pathogen Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method)

Reproductive Panel (10 targets)  CHE-STD10-101

[Packing Specifications]

12 tests / box

[Applicable Models]

Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer

[Download Brochure]

Reproductive Panel (10 targets) Chenghui-Multi-Disc-10-Reproductive-Tract-Pathogen-Nucleic-Acid-Detection-Kit-Brochure.pdf



No Data

Testing Process

No Data

Intended Use


10 Reproductive Tract Pathogen Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method) is a Fluorescent PCR-Chip assay intended for the qualitative detection of 10 pathogens in male urethral swabs and female cervical swabs. The pathogens that can be detected include:

  1. Mycoplasma hominis (MH), 

  2. Herpes simplex virus type 2 (HSV-II), 

  3. Ureaplasma urealyticum (UU), 

  4. Trichomonas vaginalis (TV), 

  5. Neisseria gonorrhoeae (NG), 

  6. Herpes simplex virus type 1 (HSV-I), 

  7. Mycoplasma genitalium (MG), 

  8. Haemophilus ducreyi (HD), 

  9. Gardnerella vaginalis (GV), 

  10. Ureaplasma parvum (UP),

  11. Chlamydia trachomatis (CT*, RUO).


Remark: The CE certificate is not yet acquired for the detection target of Chlamydia trachomatis (CT). Nevertheless, we are able to supply this test target for research use only (RUO).

Clinical Challenges


Reproductive tract infections (RTIs), including sexually transmitted infections (STIs), pose a substantial global public health burden and are a frequent clinical concern in gynecology, urology and inpatient care settings. Conventional diagnostic approaches face four core unmet needs:


Diverse pathogen spectrum with high missed diagnosis in mixed infections

RTIs are caused by a wide range of pathogens spanning bacteria, viruses, mycoplasma and protozoa, with a high rate of mixed infections. Traditional diagnostics such as microscopy, bacterial culture and single-target PCR have limited coverage and low sensitivity, often missing atypical pathogens like Mycoplasma genitalium, resulting in unclear etiology, recurrent infection and delayed intervention.


Long turnaround time delays targeted treatment

Traditional culture-based testing requires 2–7 days to generate results, while centralized molecular testing adds extra time for sample transfer and batch processing. Clinicians frequently rely on empiric antimicrobial therapy, which leads to inappropriate medication, rising antimicrobial resistance, and elevated risks of complications including pelvic inflammatory disease (PID), infertility and mother-to-child transmission.


High barriers to decentralized molecular testing

Conventional nucleic acid testing relies on standardized PCR laboratories and certified technical personnel, making it difficult to deploy in gynecology, urology, dermatology-venereology departments or inpatient wards. This results in extended sample turnaround time (TAT) and reduced diagnostic efficiency.


Unbalanced throughput for public health screening

Large-scale STI screening and public health surveillance demand a balance of speed and batch processing capacity. Conventional methods cannot meet this requirement, hindering rapid population-level screening and timely control of infection transmission sources.


Core Clinical Benefits


The 10 Reproductive Tract Pathogen Nucleic Acid Detection Kit, paired with the Multi-Disc fully automated nucleic acid analysis platform, directly addresses the above clinical and public health pain points to deliver measurable diagnostic value:


One-stop comprehensive etiological profiling

The kit covers 10 CE-marked core reproductive tract pathogens across bacteria, viruses, mycoplasma, ureaplasma and protozoa, with an additional Chlamydia trachomatis (CT) target available for research use only (RUO). A single run identifies both single and mixed infections, drastically reducing missed diagnosis rates and providing complete etiological evidence to guide precision treatment.


Rapid around 80 minutes results to optimize clinical management

Total testing time is only around 80 minutes, with just 1 minute of hands-on sample loading. Same-day diagnostic results allow clinicians to shift promptly from empiric therapy to targeted treatment, cut unnecessary antibiotic use, curb antimicrobial resistance, shorten disease duration, and lower the risk of long-term complications such as infertility and PID.

Reproductive Panel (10 targets)


Decentralized testing with low operational barriers

Powered by the fully automated Multi-Disc platform, the assay requires no specialized molecular laboratory or trained technicians, and can be deployed directly in clinical departments and inpatient wards. It significantly shortens sample TAT, improves diagnostic efficiency for both outpatient and inpatient settings, and elevates patient care experience.


High-sensitivity detection for early intervention and public health control

Built on real-time fluorescent PCR technology, the assay delivers far higher sensitivity and specificity than traditional microscopy and culture methods. It detects low-load pathogens and early-stage infections to enable early intervention, reduce transmission risk, and support efficient large-scale STI screening for public health programs.


Core Product Advantages


Reproductive Panel (10 targets)

Clinically optimized 10-plex panel design

The panel is tailored for reproductive care scenarios, covering 10 high-prevalence pathogens associated with STIs and common genital tract inflammation, suitable for gynecology, urology, dermatology-venereology and inpatient infection screening. The additional RUO Chlamydia trachomatis target supports both clinical diagnosis and research applications.


Fully automated closed sample-to-result workflow

Leveraging proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, realizing true "load-and-go" detection.



Balanced throughput for diverse clinical scenarios

Compatible with the Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer, the platform supports parallel testing of 4 samples per run with full results available in around 80 minutes. This balance of speed and batch capacity meets the needs of inpatient testing, specialist outpatient care and public health mass screening.


Lyophilized reagents for room-temperature storage and transport

With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance and greatly reducing storage and distribution costs for facilities of all sizes.


Zero cross-contamination closed cartridge system

Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces laboratory quality control burden, and ensures consistent, reliable test results.


CE-compliant with broad clinical sample compatibility

Validated for two mainstream clinical sample types — male urethral swabs and female cervical swabs. All targets are CE-marked except Chlamydia trachomatis (RUO), meeting regulatory requirements for clinical and research use in global markets.